The China Securities Regulatory Commission (CSRC) has issued a public notice on supplementary material requirements for overseas listing filings from May 11 to May 15, 2026. In the notice, the CSRC has requested that Geneplus provide additional explanations regarding the reasonableness of the share prices for investors who became shareholders within the last 12 months, as well as the reasons for any discrepancies in share prices among different investors. The company is required to provide a definitive conclusion on whether the share prices for these recent investors are fair and reasonable, and whether there is any improper transfer of benefits.
Furthermore, Geneplus must clarify whether there are any relationships among shareholders holding less than 5% of the company. If such relationships exist, it should be determined whether their shareholdings should be aggregated, and for any holdings exceeding 5%, a thorough verification of the ultimate beneficial owners is required.
According to a disclosure made by the Hong Kong Stock Exchange on December 21, 2025, Geneplus submitted its listing application to the exchange, with CCB International and CMBC Capital serving as its joint sponsors.
Additionally, the CSRC has instructed Geneplus to provide further details on the following matters, with legal counsel required to conduct verification and issue a clear legal opinion: the composition and positions of personnel involved in the company's equity incentive plan; whether these participants have any relationships with other shareholders, directors, supervisors, or senior management of the company; and whether any individuals prohibited by laws, regulations, or national provisions from participating in corporate equity incentives are included. The company must also address the fairness of the share prices, the terms of relevant agreements, the decision-making procedures followed, and the standard operational practices, providing a definitive conclusion on compliance and the absence of any improper benefit transfers.
Regarding business operations, Geneplus is requested to explain: (1) the status of obtaining relevant business qualifications and, in conjunction with the Special Administrative Measures for Foreign Investment Access (Negative List) (2024 Edition), clarify whether the business and scope of operations of the company and its subsidiaries involve areas restricted or prohibited by the negative list, and whether they will continue to comply with foreign investment access policies before and after the listing and the implementation of the "full circulation" mechanism; (2) whether the company's services in drug R&D empowerment and clinical research and transformation involve artificial intelligence fields such as large AI models, and whether they comply with the Measures for the Management of Generative Artificial Intelligence Services.
The company must also clarify whether the shares held by shareholders intending to participate in the "full circulation" mechanism are subject to pledges, freezes, or other encumbrances. Additionally, it should provide an update on the progress of state-owned shareholders in fulfilling state-owned share identification and other state asset management procedures.
According to its prospectus, Geneplus is a leading precision medicine company in China, deeply integrating AI capabilities into every core segment of the biomarker value chain. The company is dedicated to accelerating the large-scale clinical application of AI-driven multi-omics technologies through an innovative framework that synergizes multi-omics and AI, aiming to better serve the growing unmet major medical needs of China's vast patient population.
Data from CIC indicates that, based on 2024 revenue, the company ranks third in China's precision diagnostic solutions market.
Comments